ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
ITM
Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company,
Helmholtz Munich and the Departments of Neurosurgery and Nuclear Medicine at
the University Hospital Münster announced the start of a Phase I clinical trial
with ITM’s drug candidate ITM-31. ITM-31 (formerly LuCaFab), is a carbonic
anhydrase (CA) XII-specific antibody Fab fragment developed by Helmholtz Munich
coupled with ITM's medical radioisotope, non-carrier-added lutetium-177 (n.c.a
177Lu, EndolucinBeta®). ITM-31 is a novel Targeted Radionuclide Therapy
candidate for the treatment of malignant glioblastoma. The
investigator-initiated trial is
sponsored by the University Hospital Münster, conducted in hospitals in
Münster, Essen, Cologne, Würzburg, and supported by ITM and Helmholtz Munich.
Patient recruitment for the study is ongoing.
To read more please visit:
Source:
ITM